2025-523845-90-00招募中1 期
Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 76
- 试验地点
- 23
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Affairs
Scientific
CRISPR Therapeutics AG
研究点 (23)
Loading locations...
相似试验
招募中
1 期
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)NCT07392255Complement Therapeutics75
招募中
2 期
A Phase 2 Study of PTX-100 Monotherapy in Patients with r/r CTCL2025-521852-45-00Prescient Therapeutics Limited25
招募中
2 期
A Study of CX11 Tablets in Patients With Type 2 Diabetes MellitusNCT07340320Corxel Pharmaceuticals240
招募中
2 期
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725Netherton Syndrome2025-521973-16-00Biocryst Pharmaceuticals Inc.2
招募中
1 期
Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult MalesNCT07450521Mediar Therapeutics8